Portal de Periódicos da CAPES

MP48-11 CARDIOVASCULAR ADVERSE EVENTS-RELATED TO GNRH AGONISTS AND GNRH ANTAGONISTS: ANALYSIS OF REAL-LIFE DATA FROM EUDRA-VIGILANCE DATABASE

2022; Lippincott Williams & Wilkins; Volume: 207; Issue: Supplement 5 Linguagem: Inglês

10.1097/ju.0000000000002619.11

1527-3792

Cosimo De Nunzio, Antonio Nacchia, Antonio Cicione, Beatrice Turchi, Giacomo Gallo, Carmen Gravina, Alessandro Guercio, Jordi Stira, Lorenzo Maria Rivesti, Antonio Franco, Elisa Mancini, Olivia Alessandra Voglino, Valeria Baldassarri, Giorgio Guarnotta, Ferdinando Di Giacomo, G Disabato, Andrea Tubaro,

Blood Pressure and Hypertension Studies

You have accessJournal of UrologyCME1 May 2022MP48-11 CARDIOVASCULAR ADVERSE EVENTS-RELATED TO GNRH AGONISTS AND GNRH ANTAGONISTS: ANALYSIS OF REAL-LIFE DATA FROM EUDRA-VIGILANCE DATABASE Cosimo De Nunzio, Antonio Nacchia, Antonio Cicione, Beatrice Turchi, Giacomo Gallo, Carmen Gravina, Alessandro Guercio, Jordi Stira, Lorenzo Maria Rivesti, Antonio Franco, Elisa Mancini, Olivia Alessandra Voglino, Valeria Baldassarri, Giorgio Guarnotta, Ferdinando Di Giacomo, Giuseppe Disabato, and Andrea Tubaro Cosimo De NunzioCosimo De Nunzio More articles by this author , Antonio NacchiaAntonio Nacchia More articles by this author , Antonio CicioneAntonio Cicione More articles by this author , Beatrice TurchiBeatrice Turchi More articles by this author , Giacomo GalloGiacomo Gallo More articles by this author , Carmen GravinaCarmen Gravina More articles by this author , Alessandro GuercioAlessandro Guercio More articles by this author , Jordi StiraJordi Stira More articles by this author , Lorenzo Maria RivestiLorenzo Maria Rivesti More articles by this author , Antonio FrancoAntonio Franco More articles by this author , Elisa ManciniElisa Mancini More articles by this author , Olivia Alessandra VoglinoOlivia Alessandra Voglino More articles by this author , Valeria BaldassarriValeria Baldassarri More articles by this author , Giorgio GuarnottaGiorgio Guarnotta More articles by this author , Ferdinando Di GiacomoFerdinando Di Giacomo More articles by this author , Giuseppe DisabatoGiuseppe Disabato More articles by this author , and Andrea TubaroAndrea Tubaro More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002619.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: GnRH agonists and GnRH antagonists are two of the mainstay of hormonal therapy (HT) for prostate cancer. These drugs are at increased risk of cardiovascular adverse events (AEs). Aim of our study was to compare real-life data on AEs associated with GnRH agonists and GnRH antagonists based on Eudra-Vigilance reported AEs. METHODS: Eudra-Vigilance database is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA). We recorded the number of cardiac and vascular disorders for degarelix, buserelin, goserelin, leuprorelin, triptorelin per category and severity until September 2021. Pooled Relative Risk (PRR) was used to compare data between drugs. RESULTS: Overall, the number of AEs reported were for Degarelix 1943, for Buserelin 539, for Goserelin 4684, for Leuprorelin 14687, for Triptorelin 3223. The risk of cardiovascular disorders was higher for GnRH agonists than GnRH antagonists with a frequency of 3-12% vs 7-8% respectively (p <0,05). Overall GnRH antagonists presented lower risk of hypertension (PRR 0,60 (95% CI 0,37-0,98), p 0,04) and of myocardial infarction (PRR 0,05 (95% CI 0,01-0,39), p <0,01) when compared to GnRH agonists. In particular, Degarelix presented lower risk of hypertension when compared to Goserelin (PRR 0,49 (95% CI 0,30-0,87), p 0,01) and to Triptorelin (PRR 0,45 (95% CI 0,23-0,64), p <0,01. Moreover, Degarelix presented lower risk of thrombosis (PRR 0,57 (95% CI 0,02- 0,80), p 0,03) when compared to leuprorelin. No significative differences were reported regarding atrial fibrillation, cerebrovascular accidents, T.I.A., stroke and embolism events (Table). Most of the reported cardiovascular disorders for drugs were present in the 65-85 range of age. CONCLUSIONS: Real life data is consistent with registry studies regarding side effects related to HT. Real-life data suggest GnRH agonists are associated with higher cardiovascular AEs when compared to GnRH antagonists. Clinicians should consider these data when prescribing HT especially in young patients. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e825 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Cosimo De Nunzio More articles by this author Antonio Nacchia More articles by this author Antonio Cicione More articles by this author Beatrice Turchi More articles by this author Giacomo Gallo More articles by this author Carmen Gravina More articles by this author Alessandro Guercio More articles by this author Jordi Stira More articles by this author Lorenzo Maria Rivesti More articles by this author Antonio Franco More articles by this author Elisa Mancini More articles by this author Olivia Alessandra Voglino More articles by this author Valeria Baldassarri More articles by this author Giorgio Guarnotta More articles by this author Ferdinando Di Giacomo More articles by this author Giuseppe Disabato More articles by this author Andrea Tubaro More articles by this author Expand All Advertisement PDF DownloadLoading ...